EcoPhage
PrivateLast Round
Grant
Nov 20, 2023
Total Funding Raised
$2.57M
Company Overview
EcoPhage operates in Healthcare & Life Sciences and is based in Ness Ziona. Its latest recorded funding round was a Grant round in November 2023.
EcoPhage is an agri-biotechnology company that develops sustainable and effective, phage-based crop protection solutions to manage bacterial plant diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EcoPhage Comparables
Compare EcoPhage with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Phagelux AgriHealth | 89% | |
| Exacta BioScience | 80% | |
| Enviroinvest Zrt. | 75% |
For institutional investors. Book with your work email.
EcoPhage Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Nov 20, 2023 | ||||
| VC Round | Nov 22, 2022 | ||||
| Grant | Aug 1, 2022 | ||||
| Accelerator | Jul 26, 2021 | ||||
| Seed | Jul 10, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
EcoPhage Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Israel Innovation Authority | Grant |
| Israel Innovation Authority | Grant, Seed |
| MassChallenge Israel | Accelerator |
| The Trendlines Group | VC Round, Follow-on Offering, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 20, 2025
Developing a bacteriophage platform for agricultural applications.
- Sep 20, 2025
Dr. Lu Wei Liu appointed to the Board of Directors.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withSep 24, 2026
On Sep 24th '26, EcoPhage Ltd. and CNI Ag partner under a non-exclusive distribution agreement to market and sell GoldenEco(R), a phage-based biological product for bacterial diseases in tomatoes and peppers, in the United States.
- launchesSep 16, 2026
EcoPhage Ltd. will work with U.S. commercial partners to prepare the launch of GoldenEco(R), a phage-based biopesticide designed to help growers manage bacterial diseases in high-value crops, following EPA approval.
For institutional investors. Book with your work email.
EcoPhage Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about EcoPhage's valuation, stock price, and market status.
Is EcoPhage a public or private company?
EcoPhage is a private company.
What is the current stock price of EcoPhage?
EcoPhage is a private company, so its shares have no public market price. Caplight tracks EcoPhage's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is EcoPhage worth (valuation)?
Valuation information for EcoPhage is not publicly available.
Can I buy EcoPhage stock?
EcoPhage shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was EcoPhage's last funding round?
EcoPhage's most recent funding round was Grant on November 20, 2023.
Who are the main investors in EcoPhage?
Key investors in EcoPhage include The Trendlines Group.
Will EcoPhage IPO soon?
No public IPO plans have been announced for EcoPhage.
How can I track EcoPhage secondary market activity?
Caplight tracks bids, offers, and trades in EcoPhage's shares on secondary markets.